Biotechnology Entrepreneurialism:

"How Scientific Discoveries Translate into a Business Opportunity" or "So You Want to Spin Out a Company!"

Wednesday, 24 June, 08:30-12:30

Are you contemplating launching a start-up? Want to know the expectations of VCs and Pharma when they are considering a new opportunity? Wondering what the new company looks like and how it would function? Don’t miss this great opportunity to get answers to these questions and more as you network with your peers and representatives from industry, academia and biopharma as well as successful entrepreneurs. Gain first-hand knowledge on how to develop a business plan and pitch your idea. Join our experts to hear their personal experiences and views to help accelerate your research profile and expand your vision of novel funding models while potentially forging new collaborations.

Introductory Remarks8:30-8:40
Part I: Case Studies8:40-10:40 (Click to Expand)

Academic to Start-up Experience

Kenneth R. Chien, MD, PhD 
Karolinska Institutet / Wallenberg-Karolinska CardioVascular Initiative, Department of Cell and Molecular Biology and Medicine and Scientific Co-Founder of Moderna Therapeutics

Allen C. Eaves MD, PhD, FRCPC
Founder, Owner and Chief Executive Officer, STEMCELL Technologies Inc

Hans S. Keirstead, PhD 
President, NeoStem Oncology

Venture Capital perspective

Robert Millman, JD
CEO and Co-Founder, Semma Therapeutics, USA

Large pharma views on investing, partnering and innovation translation

Kenneth Drazan, MD
Head, Johnson & Johnson Innovation, California

Large Biotechnology to startup experience

Thomas J. Livelli
Vice President, Life Sciences, Promega Corporation


Annika Espander, BSc, MBA
Chief Executive Officer and Founder, Asperia AB

Break/Network 10:40-11:00
Part II: Interactive Panel Discussion 11:00-11:30
Panel and Audience Discussion 11:30-12:15
Closing 12:15-12:30

ISSCR Industry Committee 

Chair: Timothy Allsopp, BSc PhD,
Neusentis Regenerative Medicine, United Kingdom
Chair: Jiwen Zhang, PhD, GE Healthcare, United States

Asano Asami-Odaka, PhD,
Takeda Pharmaceutical Co. Ltd., Japan
Lauren Drowley, PhD, AstraZeneca, Sweden
Julie Holder, PhD,
Roslin Cells Limited, United Kingdom
Johan Hyllner, PhD,
Cell Therapy Catapult, United Kingdom
Ravi Jagasia, PhD,
F. Hoffmann-La Roche, Basel, CNS Research, Switzerland
Anish Sen Majumdar, MSc, PhD,
Stempeutics Research Private Ltd., India
Chris Mason, MD, PhD,
University College London, United Kingdom
Michael H. May, PhD,
Centre for Commercialization of Regenerative Medicine (CCRM), Canada
John D. McNeish, PhD,
GlaxoSmithKline, United States
Kristian Tryggvason, PhD,
BioLamina, Sweden
Mark Zimmerman, PhD,
Janssen R&D, United States
Claudia Zylberberg, PhD,
Akron Biotech, United States